Dr. Shukla's Laboratory

Urology Research Laboratory
  • Sanjeev Shukla, Ph.D.

    Sanjeev Shukla, Ph.D.

    Assistant Scientist

    Director, Urology Laboratory Operations

    Specializes in Zoology


Dr. Sanjeev Shukla joined the University of Florida College of Medicine – Jacksonville as an assistant scientist in the Department of Urology in 2019.

Shukla graduated with an MS degree in zoology from the University of Lucknow in Lucknow, India. Shukla then went on to obtain his Ph.D. in bio-membranes toxicology and molecular oncology from Kanpur University in Kanpur, India. He continued his postdoctoral training at the Indian Institute of Toxicology Research in Lucknow, India. Following this, Shukla received additional postdoctoral training at the departments of biochemistry and anatomy at King George's Medical University in Lucknow, India.

Shukla joined the department of urology at the Case Western Reserve University in Cleveland where he continued his translational prostate cancer research investigating cell signaling and signal transduction pathways, gene expression, the regulatory role of oncogenes/tumor suppressors and preclinical tumorigenesis models.

Research Interests

  • Developing biomarkers for cancer: discover, develop, and validate biomarkers for risk assessment, detection, and molecular diagnosis and prognosis of early cancer. Testing of new biomarkers and biomarker assays for risk assessment, detection, and molecular diagnosis and prognosis of cancers.
  • Preventive and therapeutic approaches for cancer: natural dietary and synthetic agents - evaluation of cancer chemo-preventive potential of natural constituents employing in cell culture and animal settings. Models include prostate. Cellular, biochemical and molecular mechanisms employing biochemical and molecular biological techniques.
  • Cancer preventive and therapeutic mechanism includes: oncogenes and suppressor genes, transcription factors, cyclin dependent kinases, cyclin dependent kinase inhibitors, apoptosis and anti-apoptotic signaling pathways.
  • Other area includes: male infertility, diabetes, obesity in relation to cancer.

Selected Publications

  1. Verma S, Shukla S, Pandey M, MacLennan GT, Gupta S. Differentially Expressed Genes and Molecular Pathways in an Autochthonous Mouse Prostate Cancer Model. Front Genet. 26; 10:235, 2019. PMCID: PMC6445055
  2. Oak C, Khalifa AO, Isali I, Bhaskaran N, Walker E, Shukla S. Diosmetin suppresses human prostate cancer cell proliferation through the induction of apoptosis and cell cycle arrest. Int J Oncol. 53(2):835-843, 2018. PMCID: PMC6017185
  3. Patel R, Khalifa AO, Isali I, Shukla S. Prostate cancer susceptibility and growth linked to Y chromosome genes. Front Biosci (Elite Ed). 10:423-436, 2018. PMCID: PMC6152832
  4. Shukla S, Shankar E, Fu P, MacLennan GT, Gupta S. Suppression of NF-κB and NF-κB-Regulated Gene Expression by Apigenin through IκBα and IKK Pathway in TRAMP Mice. PLoS One. 10(9):e0138710, 2015. PMCID: PMC4574560
  5. Shukla S, Sharma H, Abbas A, MacLennan GT, Fu P, Danielpour D, Gupta S. Upregulation of SATB1 is associated with prostate cancer aggressiveness and disease progression. PLoS One. 2013; 8(1):e53527. doi:10.1371/journal.pone.0053527. Epub 2013 Jan 7. PMCID: PMC3538595
  6. Shukla S, Shukla M, Maclennan GT, Fu P, Gupta S. Deregulation of FOXO3A during prostate cancer progression. Int J Oncol. 34(6):1613-20, 2009. PMID: 19424579
  7. Shukla S, Maclennan GT, Flask CA, Fu P, Mishra A, Resnick MI, Gupta S. Blockade of {beta}-Catenin Signaling by Plant Flavonoid Apigenin Suppresses Prostate Carcinogenesis in TRAMP Mice. Cancer Res. 67(14):6925-35, 2007. PMID: 17638904
  8. Shukla S, Mishra A, Fu P, MacLennan GT, Resnick MI, Gupta S. Up-regulation of insulin-like growth factor binding protein-3 by apigenin leads to growth inhibition and apoptosis of 22Rv1 xenograft in athymic nude mice. FASEB J. 19(14):2042-4, 2005. PMID: 16230333
  9. Shukla S, MacLennan GT, Fu P, Patel J, Marengo SR, Resnick MI and Gupta S: Nuclear factor-kappaB/p65 (Rel A) is constitutively activated in human prostate adenocarcinoma and correlates with disease progression. Neoplasia, 6(4): 390-400, 2004. PMCID: PMC1502112